Search research articles
Contact Us
Filters
Showing results (161-170 of 323) with videos related to
Page
of 33
Sort By:
Leukemia
|
March 7, 2024
The dual HCK/BTK inhibitor KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma
Hildo C Lantermans, Fangxue Ma, Annemieke Kuil, et al.
Blood Advances
|
August 22, 2020
Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up
Jorge J Castillo, Kirsten Meid, Catherine A Flynn, et al.
International Journal of Cancer
|
December 19, 2022
Dysfunctions of innate and adaptive immune tumor microenvironment in Waldenström macroglobulinemia
Danka Cholujova, Gabor Beke, Zachary R Hunter, et al.
Cancer Research
|
March 15, 2024
Retraction: Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications
Yu-Tzu Tai, Laurence P Catley, Constantine S Mitsiades, et al.
Blood
|
July 1, 2006
Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications
Masood A Shammas, Paola Neri, Hemanta Koley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 10, 2008
Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs
Xavier Leleu, Jacob Soumerai, Aldo Roccaro, et al.
Blood
|
November 19, 2008
Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia
Steven P Treon, Andrew R Branagan, Leukothea Ioakimidis, et al.
Blood
|
February 7, 2009
International prognostic scoring system for Waldenstrom macroglobulinemia
Pierre Morel, Alain Duhamel, Paolo Gobbi, et al.
Cancer Research
|
April 17, 2004
Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications
Yu-Tzu Tai, Laurence P Catley, Constantine S Mitsiades, et al.
Oncotarget
|
April 21, 2017
The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions
Antonio Sacco, Adriano Fenotti, Loredana Affò, et al.
Page
of 33
Search research articles
Search
Showing results (161-170 of 323) with videos related to
Sort By:
Page
of 33
Leukemia
|
March 7, 2024
The dual HCK/BTK inhibitor KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma
Hildo C Lantermans, Fangxue Ma, Annemieke Kuil, et al.
Blood Advances
|
August 22, 2020
Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up
Jorge J Castillo, Kirsten Meid, Catherine A Flynn, et al.
International Journal of Cancer
|
December 19, 2022
Dysfunctions of innate and adaptive immune tumor microenvironment in Waldenström macroglobulinemia
Danka Cholujova, Gabor Beke, Zachary R Hunter, et al.
Cancer Research
|
March 15, 2024
Retraction: Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications
Yu-Tzu Tai, Laurence P Catley, Constantine S Mitsiades, et al.
Blood
|
July 1, 2006
Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications
Masood A Shammas, Paola Neri, Hemanta Koley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 10, 2008
Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs
Xavier Leleu, Jacob Soumerai, Aldo Roccaro, et al.
Blood
|
November 19, 2008
Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia
Steven P Treon, Andrew R Branagan, Leukothea Ioakimidis, et al.
Blood
|
February 7, 2009
International prognostic scoring system for Waldenstrom macroglobulinemia
Pierre Morel, Alain Duhamel, Paolo Gobbi, et al.
Cancer Research
|
April 17, 2004
Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications
Yu-Tzu Tai, Laurence P Catley, Constantine S Mitsiades, et al.
Oncotarget
|
April 21, 2017
The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions
Antonio Sacco, Adriano Fenotti, Loredana Affò, et al.
Page
of 33